Non-Steroidal Therapies and Targeted Inflammation in Seborrheic Dermatitis

This episode, titled Non-Steroidal Therapies and Targeted Inflammation in Seborrheic Dermatitis, features dermatologists discussing the following critical questions:

How do non-steroidal therapies fit into the evolving treatment paradigm for SD particularly in addressing chronic inflammation and long-term management needs?

Can you describe the mechanism of action of phosphodiesterase 4 (PDE-4) inhibition, and how increasing intracellular cyclic adenosine monophosphate (cAMP) leads to targeted inflammation control in SD?

Led by Dr. Bunick, Dr. Ungar examined non-steroidal therapies becoming increasingly important in the evolving management of seborrheic dermatitis (SD), particularly for patients who require long-term disease control or have sensitive areas such as the face and intertriginous regions. Unlike corticosteroids, which primarily provide short-term symptom relief, non-steroidal agents aim to modulate the underlying inflammatory pathways driving chronic disease. Phosphodiesterase 4 (PDE-4) inhibitors represent a promising class of non-steroidal therapies for SD. PDE-4 inhibition increases intracellular cyclic adenosine monophosphate (cAMP) levels, which in turn downregulates pro-inflammatory cytokine production, including key mediators in the Th17/Th22 pathways implicated in SD. By targeting these specific inflammatory mechanisms, PDE-4 inhibitors help reduce erythema, scaling, and pruritus while minimizing systemic or local adverse effects associated with long-term steroid use. These agents also support barrier restoration, complementing other therapies that address microbial triggers or keratinocyte turnover. The targeted nature of PDE-4 inhibition allows for safer chronic use, making it a valuable option for maintaining disease control over time. Overall, non-steroidal therapies are shifting the treatment paradigm toward more precise, mechanism-based management of SD.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, Comparing Mechanisms and Use of Antifungals and PDE-4 Inhibitors in Seborrheic Dermatitis, panelists will continue their discussion and highlight how antifungal therapies, such as ketoconazole, target Malassezia colonization, whereas PDE-4 inhibitors, like roflumilast, modulate intracellular cAMP to control inflammation. It also highlights how formulation and vehicle characteristics influence efficacy, tolerability, and patient adherence in the clinical management of SD.